Implantable assembly

ABSTRACT

An implantable assembly is described for acquisition of neuronal electrical signals at a selected location which propagate along at least one nerve fiber contained in a nerve fiber bundle, as well as for selective electrical stimulation of the at least one nerve fiber, having: an implantable electrode assembly (E) which is disposed on a biocompatible support substrate which can be positioned around the nerve fiber bundle in a cuff, which has a cylindrical support substrate surface (i) which in the implanted condition is orientated facing the nerve fiber bundle, on which a first electrode assembly for locationally selective acquisition of the neuronal electrical signals and selective electrical stimulation of the at least one nerve fiber, and on which a second electrode assembly is disposed to record an ECG signal, and an analysis and control unit (A/S) which can be electrically conductively connected or is connected to the implantable electrode assembly (E), in which the locationally selective acquired neuronal electrical signals as well as the ECG signal can be analyzed in a time-resolved manner such that a neuronal time signal correlated with a physiological parameter, such as blood pressure, can be derived.

CROSS-REFERENCE TO RELATED APPLICATIONS

Reference is made to International Application No. PCT/EP2015/073131filed Oct. 7, 2015, and German Patent Application No. 10 2014 014 942.0,filed Oct. 7, 2014, which applications are incorporated herein byreference in their entirety.

BACKGROUND OF THE INVENTION Technical Field

The invention relates to an implantable assembly for locationallyselective acquisition of neuronal electrical signals which propagatealong at least one nerve fiber contained in a nerve fiber bundle, aswell as to selective electrical stimulation of the at least one nervefiber. The implantable assembly comprises an implantable electrodeassembly which can be positioned around a nerve fiber bundle in a cuff,by which electrical signals can be applied to selected nerve fiberswithin the nerve fiber bundle. The electrical stimulation is inparticular carried out by specifically manipulating the blood pressurein an animal or human patient.

Description of the Prior Art

Arterial hypertension is a global and typical disease of civilizationwhich threatens the lives of millions of patients and at the same timeplaces a huge burden on the health services. Therapeutic measures untilnow have been based on the administration of blood pressure-reducingmedication such as ACE inhibitors, beta blockers, etc., but in additionto the desired blood pressure-reducing effect, they are associated withsubstantial side effects such as, for example, bradycardia, heartfailure, asthma attacks, etc. In addition, despite the development ofnew blood pressure-reducing drugs, in up to 30% of all patients takingsimilar medication, a sufficient target blood pressure cannot beobtained. See the paper by H R Black et al., “Principal Results of theControlled Onset Verapamil Investigation of Cardiovascular End Points(Convince)”, TRIAL, Jama, 289 (16), pp 2073-2082, 2003.

A further therapeutic approach to combatting high blood pressure followson from a study by the Applicant which has been published in the articleby Dennis T T Plachta, Oscar Cota, Thomas Stieglitz, MortimerGierthmuehlen, “Selektive Ableitung and Stimulation fur einblutdrucksenkendes Implantat unter Verwendung vonVielkanal-Cuff-Elektroden” [Selective Recording and Stimulation for aBlood Pressure-Reducing Implant Using Multi-Channel Cuff Electrodes],tm-Technisches Messen, 2013, vol 80 (5), pp 163-172. The resultsobtained by animal tests carried out on rats give rise to thepossibility of detecting neuronal electrical signals in a locationallyresolved manner from the nerve fiber bundle section by an electrodeassembly implanted on a nerve fiber bundle section of the vagus nerve,as well as applying electrical signals to selected nerve fibers tostimulate them for the purposes of a technologically initiated bloodpressure reduction. Stimulation of the vagus nerve of this type thus inprinciple has the potential of becoming an alternative treatment fortherapy-refractory blood pressure.

The concept of selective vagus nerve stimulation is based on many years'experience in applying and establishing neuromodulatory therapy ofsevere forms of epilepsy, in which the vagus nerve is electricallystimulated in its entirety with the aid of an implanted electrodeassembly in order to mitigate at least their extent as regardingseverity and duration of incipient epileptic episodes. In this regardsee F Sidiqui et al. “Cumulative Effect of Yagus Nerve Stimulators onIntractable Seizures Observed Over a Period of 3 Years”, Epilepsy andBehavior, 18 (3), pp 299-302, 2010, as well as T Stieglitz,“Neuroprothetik und Neuromodulation—Forschungsansatze und klinischePraxis bei Therapie und Rehabilitation” [Neuroprosthetics andneuromodulation—research strategies and clinical practice in therapy andrehabilitation],Bundesgesundheitsblatt—Gesundheitsforschung—Gesundheitsschutz, 53 (8),pp 783-790, 2010.

In contrast, for the chronic treatment of hypertension, the fibersrelevant to blood pressure initially have to be located metrologicallyin order to then selectively electrically stimulate them in a particularmanner. In order to protect the vagus nerve as far as possible from thepositioning of an electrode assembly by implantation and in order toirritate the epineurium of the vagus nerve as little as possible, in thecited contribution by Dennis T T Plachta et al., the use of what isknown as a cuff electrode is proposed which can be extraneurallyattached to the vagus nerve. This has the advantage that the cuffelectrode is relatively easy to position along the vagus nerve and,moreover, means that surgical intervention is only slightly invasive fora patient and thus goes easy on the patient and is also rapid to carryout.

The baroreflex acts to regulate blood pressure naturally; it constitutesa homeostatic, self-regulating mechanism and reflexively activatesvarious effectors in the event of an elevated blood pressure. The heartrate is reduced, inter alia, as well as dilating the arterial vessels inorder to reduce the blood pressure. In the case of a low blood pressure,the baroreflex is suppressed, whereupon the heart rate rises and bloodvessels are constricted so that the blood pressure rises once again. Thesensory inputs for the baroreflex are known as baroreceptors which,inter alia, are located in the walls of the aortic arch. From here, theblood pressure information runs monosynaptically along the nerve fibersrelevant to blood pressure, hereinafter termed baroreceptive fibers, tothe brain stem. When a threshold for the blood pressure is exceeded, thebaroreflex triggers inhibition of sympathetic nerve fibers, leading toan immediate drop in the blood pressure. With the aid of the cuffelectrode shown here in FIGS. 2a and 2b , it is possible to exploit thisbaroreflex mechanism by selectively detecting the pressure informationsupplied to the brain stem and simultaneously selectively “overwriting”it in order in this manner to suggest a substantially increased bloodpressure situation to the brain stem, whereupon a natural significantdrop in blood pressure is initiated.

FIG. 2a shows the known cuff electrode E in a planar view, in a planarunfolded state. FIG. 2b shows the cuff electrode E when implanted, inwhich regions B1 and B2 of the cuff electrode E have been folded on topof each other in order to save space and, moreover, a support substrateregion 1B of the cuff electrode E provided with a first electrodeassembly 2 surrounds a region of the nerve fiber bundle NFB in a cuff.

The cuff electrode E consists of a flexible, biocompatible supportsubstrate 1 which in the embodiment shown is a polyimide filmapproximately 11 μm thick on which is positioned, on the top of thesupport substrate facing the plane of the drawing in FIG. 2a , a firstelectrode assembly 2 composed of a plurality of individual electrodesfor the purposes of spatially resolved acquisition of neuronalelectrical signals as well as for selective electrical stimulation ofindividual nerve fibers NF running in the nerve fiber bundle NFB. Theindividual electrodes of the first electrode assembly 2 come into directsuperficial contact with the epineurium EPI of the nerve fiber bundleNFB because, by appropriate application of mechanical pretensioning, thesupport substrate 1 in the support substrate region 1B has rolled itselfup, forming a support substrate surface 1′ in the form of a rightcylinder facing the nerve fiber bundle NFB, as can be seen in FIG. 2b .In this manner, the individual electrodes of the first electrodeassembly 2 assume an annular shape in space in the circumferentialdirection U curved around the nerve fiber bundle NFB.

Both for locationally selective acquisition of neuronal electricalsignals and also for selective electrical stimulation of at least onenerve fiber NF, three first electrode structures 3 are provided whichare each disposed at equal axial distances from each other whichcomprise, in the circumferential direction U, at least two electrodecontacts 4, or eight as illustrated in the embodiment of FIG. 2a, b .The respective eight first electrode contacts 4 belonging to a firstelectrode structure 3 are disposed evenly in the circumferentialdirection U, that is at 45° with respect to each other. This enableseight-fold locational selectivity in the circumferential direction forlocationally selective acquisition of neuronal electrical signals fromthe nerve fiber bundle NFB to be investigated. The first electrodestrips 5 disposed respectively axially on both sides next to the threefirst electrode structures 3, which completely surround the nerve fiberbundle NFB, act as a ground potential in the event of locationallyselective acquisition of neuronal electrical signals. However, ifselectively targeted nerve fibers NF within the nerve fiber bundle NFBare to be stimulated electrically, then these first electrode strips 5each act as an anode or as a counter-pole.

The threefold or tripolar disposition of the respective first electrodestructures 3, by means of which respective first electrode contacts 4acquire monopolar neuronal electrical signals, or electrical signals canbe emitted for the purposes of locationally selective stimulation,allows impedance changes due to tissue growth at the metallic electrodecontacts 4 to be determined and to be eliminated by the processingtechnology; on the other hand, neuronal signals relevant to bloodpressure which run through the tripole assembly axially along anappropriate nerve fiber NF with a slight time delay, can be detected bymeans of appropriate tripolar amplification. In addition to the firstelectrode structures 3 described above as well as first electrode strips5 which each assume a circular shape, which are all are positioned onthe support substrate surface 1′ facing the plane of the drawing in FIG.2a and which end proximally in connection structures V via correspondingelectrical lines L, a second electrode assembly in the form of referenceelectrodes 12 is positioned on the rear of the support substrate 1 whichon the one hand serves to acquire the intracorporeal electricalbackground ground signal or noise level which is at the basis of thesignal analysis, on the other hand allows ECG signals to be acquiredwith the aid of the cuff electrode E. The electrode assembly which canbe implanted as a cuff electrode can be connected, via the electricalconnection structures V, with a hermetically encapsulated signaldetector and generator 6 which is also configured as an implant.

With the known implantable electrode assembly, in the context of animalexperiments on rats, it has been shown that with the aid of the total of24 first electrode contacts distributed evenly around the nerve fiberbundle NFB as tripoles, blood pressure-correlated neuronal electricaltime signals, hereinafter termed baroreceptive signals, can be acquiredwhich furthermore, because their signal level is a function ofcircumferential direction, can act to localize the baroreceptive nervefibers. Stimulation is tripolar, with that electrode contact 4 or thoseelectrode contacts 4 of the centrally disposed first electrode structure3 of the tripole assembly being used to detect the respective largestsignal level of the baroreceptive signals. It has been shown that, bymeans of selective stimulation of baroreceptive nerve fibers, the bloodpressure can be reduced reliably and significantly, wherein only veryslight bradycardia (pulse reduction below 60 beats per minute) as wellas barely noticeable bradypnoea (slowing of breathing to less than 20breaths per minute) occurred.

In order to selectively electrically stimulate the baroreceptive nervefibers, electrical stimulation signals were applied, on the basis of aspecific combination of fixed predetermined stimulation parameters, tothe respective selected electrode contacts 4 of the centrally disposedelectrode structure. In this regard, the stimulation signals in the formof electrical stimulation events were applied to the selected nervefibers at freely selectable intervals; as an example, every 20 secondsan electrical stimulus composed of 100 individual pulses was applied tothe nerve fiber bundle via the respective selected electrode contact(s).Each individual pulse in this respect had a stimulation pulse durationof 0.6 ms with an anodic or cathodic stimulation amplitude of 0.8 mArespectively, whereupon electrode polarization was made possible. With arepetition rate for the individual pulse, what is known as thestimulation frequency, of 40 Hz, the total duration of an individualelectrical stimulus was 100×25 ms, i.e. 2.5 seconds. In the stimulationexperiments carried out on rats, different respective predeterminedstimulation parameters were employed, namely a respective stimulationfrequency of 30 to 50 Hz, a stimulation pulse duration of 0.1 ms to 0.5ms as well as a stimulation amplitude of 0.3 mA to 1.5 mA.

However, although the knowledge gained in the context of the previousanimal experiments regarding manipulating the blood pressure byselective electrical stimulation of baroreceptive nerve fibers appearsto be highly promising, at least the quantitative relationships betweenthe electrical stimulation event and the biological response in the formof a drop in blood pressure initiated on the basis of an organicregulation mechanism is still poorly understood. Particularly withlarger animals than the rats used in animal experiments until now, orindeed in humans, far more regulatory stimulations have to be carriedout beforehand in order to arrive at an outcome for organic regulationwhich is within a quantitatively determined range of tolerances.

SUMMARY OF THE INVENTION

The object of the invention is an improved implantable assembly forlocationally selective acquisition of neuronal electrical signals whichpropagate along at least one nerve fiber contained in a nerve fiberbundle, and for selective electrical stimulation of at least one nervefiber with an electrode assembly as described here, in a manner suchthat the stimulative manipulation of specific regions of the vegetativenervous system, in particular the vagus nerve, can be undertaken withsignificantly greater precision for the purposes of manipulating bloodpressure. When considering carrying out such regulative measures onlarger life forms than rats, in particular on humans, it must be ensuredthat the desired neuronal, physiological and/or organic state isestablished within at least a foreseeable quantifiable range oftolerances. All of the measures required in this regard should alsoexclude undesirable biological side effects. In principle, in additionto the desired manipulating of the blood pressure, as an alternative orin combination, the assembly should also be applicable to any othervegetative but also sensorimotoric parameters for the purposes ofspecific manipulation.

In contrast to the procedure described above for electrical stimulationof at least one selected nerve fiber with respectively rigidly fixedstimulation parameters, that is stimulation pulse duration, stimulationamplitude and stimulation frequency, the implantable assembly configuredin accordance with the invention enables electrical stimulation signalsto be produced in the form having a temporal amplitude profile in apulse wave form, which is broadly comparable to natural blood pressuresignals and also is to be temporally overlaid with the natural bloodpressure signals at the baroreceptive nerve fibers, so that the naturalblood pressure signals transmitted along the baroreceptive nerve fibersfrom the baroreceptors to the brain stem can be overwritten properly. Inthis manner, unlike as before, the stimulation in accordance with theinvention does not follow a pulsating “on-off-on-off” pattern, butinstead the engineered electrical stimulation signals applied along thebaroreceptive nerve fibers are supplied to the brain stem with astimulation frequency which matches the natural signal rhythm, that isrespectively in the natural time window in which the brain stem expectsthe blood pressure signals.

The natural form of a pulse wave which runs through the baroreceptivefields in the aortic arch typically has a pulse duration of less thanone second and moreover is characterized by a strong, fast andnon-linear pulse wave rise and a subsequent slow fall, which is alsonon-linear. This mechanical pulse wave is transduced by thebaroreceptors into a neuronal electrical signal form. This neuronalelectrical signal is fed to the brain stem via the vagus nerve andcontains the information regarding the strength and duration of themechanical pulse wave. By matching this natural neuronal electricalsignal form, manipulation of the natural organic regulation mechanismengineered by the implantable assembly is carried out by temporallycoherently overwriting the natural neuronal electrical time signal withengineered electrical stimulation signals applied to the at least oneselected baroreceptive nerve fiber the amplitude level of which is aboveor below the natural neuronal electrical time signals, depending on thedesired therapeutic outcome. In this manner, the natural, organic bloodpressure regulation mechanism is not irritated or is not significantlyirritated, that is the brain stem which receives the technicallymanipulated electrical stimulation signals cannot discern any differencewith respect to the natural neuronal electrical time signals. As aresult, the natural organic regulation mechanism is activated, leadingin a completely natural manner to a regulation outcome which is in theform of a specific and expected adjustment in blood pressure.

Furthermore, the implantable assembly in accordance with the inventionoffers the possibility of autonomous control of blood pressuremonitoring, that is the natural organic regulation mechanism is onlyactivated in those events in which a significant departure from a normalblood pressure is observed. More advantageously, it is possible tooperate the implantable assembly by self-control, that is in the mannerof a closed loop function, in which the organic regulation outcomebrought about by an electrical stimulation acquires, analyses and, ifnecessary, undertakes appropriate subsequent regulation.

In this regard, the implantable assembly in accordance with theinvention for locationally selective acquisition of neuronal electricsignals which propagate along at least one nerve fiber contained in anerve fiber bundle, preferably a baroreceptive fiber, and also forselective electrical stimulation of the at least one nerve fiber, ischaracterized by the following components:

The assembly in accordance with the invention will now be described byway of an example of manipulating blood pressure as the physiologicalparameter, without limitation to the general inventive concept. Clearly,the implantable assembly may also be used to manipulate otherphysiological parameters, for example breathing rate, heart rate, bodytemperature, etc., or other clinical pictures, for example autoimmunediseases, heart rhythm problems, severe depression, epilepsy, etc. Theimplantable assembly can be used for the therapy of alternative bodyfunctions as well as other peripheral nerves or nerves of the central orvegetative nervous system. An example is the field of motorneuroprostheses following central paralysis as a consequence of spinalor brain injuries. In these cases, the sensory signals from the pressureand location receptors of the hand, for example, can be selectivelyattached to implantable assemblies and the grip strength can beself-regulated in accordance with a set point setting. In the field ofneuromodulation, the implantable assembly may also be envisaged inrehabilitation following stroke and hemiparesis. In this regard, thesensory signal can be amplified and coupled to improve the outcome ofrehabilitation. It is also possible to envisage a controlled breathstimulator employing the implantable assembly, via the phrenic nerve tothe diaphragm, modulation of the sympathetic nervous system on thesympathetic trunk or efficient pain therapy by means of highly selectiveperipheral nerve stimulation.

For the purposes of locationally selective acquisition of neuronalelectrical signals along selected nerve fibers within a nerve fiberbundle as well as for selective electrical stimulation of the at leastone selected nerve fiber, an implantable electrode assembly is providedwhich is positioned on a biocompatible support substrate which can beplaced around the nerve fiber bundle in a cuff which has a rightcylindrical support substrate surface which faces the nerve fiber bundlewhen implanted. In addition, a second electrode assembly for acquiringthe ECG signal representing the heart activity is disposed on thebiocompatible substrate. The second electrode assembly does not have tobe applied to the same support substrate surface of the supportsubstrate as the existing first electrode assembly.

The implantable electrode assembly, that is at least the first andsecond electrode assembly, is electrically connected to an analysis andcontrol unit or is configured so as to be connectable therewith, inwhich the locationally selectively acquired, neuronal electrical signalsas well as the ECG signal can be analyzed in a time-resolved manner sothat a neuronal time signal can be derived which is correlated to theblood pressure. The analysis and control unit, configured as a digitalsignal processor or microcontroller, can process signal data and alsogenerate control signals.

A first comparator unit connected to the analysis and control unit actsto determine a characteristic relative time delay between themetrologically acquired ECG signal and the neuronal time signalcorrelated with the blood pressure.

Advantageously, the time difference between the R wave of the ECG timesignal and a signal flank point along the steeply rising positive signalflank of the measured time signal correlated with the blood pressurewave is determined. The measured neuronal time signal correlated withthe pulse wave or the blood pressure is characterized by a signal formwhich is dependent on the configuration of the first electrode assemblyand is usually multiphase, to which a characteristic signal flank pointcan be assigned which acts to determine a time delay with respect to thetemporally advanced ECG signal. The time delay determined between theECG signal and the blood pressure wave or the pulse wave or the measuredtime signal correlated with the blood pressure wave also acts toprecisely match the production of engineered stimulation signals to thenatural neuronal electrical signals propagating along the baroreceptivenerve fibers.

Furthermore, the analysis and control unit determines a time windowwithin which the neuronal time signals correlated to blood pressure isover a specific amplitude level, that is the time window corresponds tothe pulse duration of a blood pressure wave. For the purposes ofmanipulating blood pressure, the aim is to apply an engineeredelectrical stimulation signal within it, with the aid of the time windowdetermined with the aid of the analysis and control unit, to the atleast one selected baroreceptive nerve fiber, so that the brain receivesthe electrical stimulation signal with a signal duration which matchesthe natural pulse wave duration and at a time at which the brain expectsthe normal, that is natural, blood pressure signals.

Furthermore, the analysis and control unit is electrically connected toa first function generator which generates, within the time windowdetermined by the analysis and control unit which has a determined timedelay with respect to the ECG signal, an electrical stimulation signalcomposed of a plurality of n individual pulses the phase and temporalamplitude profile of which are matched to the phase and temporalamplitude level of the recorded neuronal time signal correlated with thephysiological parameter, preferably blood pressure. Advantageously, theelectrical stimulation signal differs only in the temporally varyingamplitude level which, in the case of a high blood pressure therapy, isselected to be larger or higher than that of the neuronal time signalcorrelated with the natural blood pressure. In this manner, the brainreceives the information concerning a greatly increased blood pressure,to counter which appropriate natural organic regulation mechanisms areactivated.

In order to transform and pass on the electrical stimulation signalcomposed of a plurality of n individual pulses in the form of a currentsignal, the first function generator and also the first electrodeassembly of the implantable electrode assembly are directly orindirectly connected via a first signal-current converter which suppliesthe electrical stimulation signal for selective electrical stimulationof the at least one nerve fiber to the first electrode assembly.

With the exception of the implantable electrode assembly, the firstelectrode assembly of which comes into physical, that is electricalcontact with the epineurium of the nerve fiber bundle, all of theremaining components of the implantable assembly, that is the analysisand control unit, the first comparator unit, the first functiongenerator as well as the first signal-current converter are integratedinto one implantable module, that is surrounded in a fluid-tight mannerby a capsule formed from biocompatible material, wherein at least oneelectrical connection structure is provided for electrical contact ofthe components included in the implantable module with the implantableelectrode assembly.

By means of the temporally coherent matching of the selective electricalstimulation with the transmission of natural, neuronal electricalsignals along selected baroreceptive nerve fibers, as well as bymatching the stimulation signals to the signal duration and signal formof the natural baroreceptive neuronal signals, the difference is onlyreflected in a temporally varying amplitude level which is usuallyraised, that is higher compared with the natural baroreceptive signals.Clearly, it is also possible to apply smaller amplitude levels to the atleast one selected nerve fiber with the aid of the implantable assemblyin accordance with the invention. In order to quantitatively establishthe magnitude of the extra or reduced engineered amplitude, theimplantable assembly provides at least one second comparator unit whichis electrically connected to the analysis and control unit, whichcompares at least one signal level which is associated with the neuronaltime signal correlated with the blood pressure with at least onereference signal and as a result generates a differential level value.The analysis and control unit also establishes, at least on the basis ofthe determined differential level value, at least the temporal amplitudeprofile of the stimulation signal, that is if the neuronal time signalcorrelated with the blood pressure measured with the aid of theimplantable assembly differs significantly from the predeterminedreference signal then, depending on the regulation requirement, thetemporally varying amplitude level of the electrical stimulation signalis raised or reduced with respect to the measured time neuronal timesignal correlated with the blood pressure. In the event of a high bloodpressure therapy, it is usually necessary to raise the temporallyvarying amplitude level significantly in order in this manner to supplythe brain with information regarding an elevated blood pressure whichthen, in the context of natural organic or biological regulationmechanisms, will seek to reduce the detected excessive blood pressurelevel.

The electrical stimulation explained above, which is illustrated withthe aid of the cuff electrode assembly shown in FIGS. 2a and 2b , iscarried out along the baroreceptive nerve fibers with isotropic signalcoupling, that is without setting a fixed signal propagation direction,so that the electrical stimulation signals can propagate both alongafferent and along efferent nerve fibers. In order to prevent electricalstimulation signals from being propagated along efferent nerve fibers,that is directed towards the heart, without thereby exerting asignificant negative influence on non-baroreceptive, afferent as well asefferent nerve fibers within the nerve fiber bundle, a cuff electrodeassembly which is modified compared with the electrode assemblydescribed in FIG. 2 is appropriate, which is supplemented by at leastone third electrode assembly for inhibiting a unidirectional electricalsignal transmission along at least one selected nerve fiber within anerve fiber bundle.

The third electrode assembly which is also positioned on the samesupport substrate formed as a single piece on the same support substratesurface as the first electrode assembly, is in a spatially fixedassociation with the first electrode assembly, in particular with thefirst electrode contacts of the at least three first electrodestructures, with the aid of which baroreceptive nerve fibers within thenerve fiber bundle are locationally selectively acquired and, moreover,can be selectively electrically stimulated. When the localizedbaroreceptive nerve fibers are known, the third electrode assembly canbe used for the purposes of a selective inhibition of the baroreceptivenerve fibers in order to suppress further transmission of electricalstimulation signals along efferent nerve fibers, that is leading to theheart. In this regard, there are at least two, preferably four or moresecond electrode contacts of at least one third electrode structurewhich, like the first electrode contacts of one of the at least threefirst electrode structures, are distributed uniformly in thecircumferential direction of the support substrate surface orientated toface the nerve fiber bundle and forming a right cylinder. To inhibitlocalized efferent baroreceptive nerve fibers, at least one of the thirdelectrode contacts of the third electrode structure is activatedelectrically, whereupon specific, temporally limited selectiveinhibition of the efferent nerve fiber in question is carried out. Inthis regard, an electrical polarization field enters the nerve fiberbundle from the respective at least one activated third electrodecontact and interacts primarily with the nerve fiber to be inhibited. Inorder to axially limit the electrical polarization field propagated intothe nerve fiber bundle during inhibition, each third electrode structureuses second electrode strips applied axially on both sides which, whenthe cuff electrode is implanted, constitute ring electrodes whichcompletely surround the nerve fiber bundle.

For the purposes of inhibiting selected efferent nerve fibers, themodified implantable electrode assembly should be applied to the nervefiber bundle in a manner such that the additional third electrodeassembly is orientated towards the heart or the baroreceptive receptors,that is caudally, and the first electrode assembly which is concernedwith the selective acquisition of neuronal electrical signals and alsothe electrical stimulation of localized nerve fibers, is orientatedtowards the brain, that is rostrally, along the nerve fiber bundle.

With the aid of the third electrode assembly, inhibition can be carriedout either by means of what is known as an anodal block or by theapplication of sinusoidal signals with frequencies in the kilohertzrange. In the case of anodal blocking, at least one of the secondelectrode contacts is polarized anodically, whereupon a prevailingvoltage is produced at the location of the efferent nerve fiber throughwhich an activating stimulation of the appropriate nerve fiber issuppressed. Similarly, inhibition can be obtained by applying a highfrequency signal, wherein a high frequency electrical inhibition signalis applied to at least one selected third electrode contact, whereuponthe electrical signal transmission mechanisms along the efferent nervefibers come to a standstill for a brief period.

In both cases, despite being very close to the first electrodestructure, because it is so narrow, given by the axial separation ofboth third electrode strips, the third electrode assembly provided inaccordance with the invention is axially spatially limited along theefferent nerve fibers to be inhibited, although the implantableelectrode assembly should not exceed an axial length of 4 cm, so thatthe first electrode assembly disposed on the brain side along the nervefiber bundle can be coupled into the respective localized afferent nervefibers guiding electrical stimulation signals to the brain without beinginfluenced by the inhibition mechanism. In this manner, any side effectscaused by possible direct stimulation in the direction of the nervefibers leading to the heart, that is efferent nerve fibers, can beeliminated.

Advantageously, the third electrode contacts of the third electrodestructure, when the cuff electrode has been implanted, are uniformlydistributed along a virtual circle in order in this manner toselectively and effectively inhibit localized efferent nerve fibersrelative to the circumferential edge of a nerve fiber bundle.

However, in an advantageous embodiment, it is not necessary for thethird electrode contacts to be identical in form and size, wherein theiraxial extents are respectively selected so as to be identical, and thesame is the case for the axial extents of the first electrode contactsof the first three electrode structures. The circumferential extent ofthe respective third electrode contacts is selected so as to be largerthan the circumferential extent of the first electrode contacts. Thus,the third electrode contacts preferably have a larger surface areacompared with the first electrode contacts, whereupon the locationalselectivity, by means of which the third electrode contacts canelectrically polarize specific efferent nerve fibers, is smaller thanthe locational selectivity with which the first electrode contacts canelectrically stimulate localized nerve fibers. Alternatively, instead ofa rectangular shape, the third electrode contacts may also be configuredas circular contacts. This has the advantage that no voltage field peaksare formed that are caused by edges or corners.

The third electrode assembly is preferably configured in the form of atripolar electrode assembly, that is, the third electrode structure isaxially bordered on both sides by a third electrode strip eachconfigured as a ring, wherein the axial distance between two thirdelectrode strips along the support substrate is preferably selected soas to be between 0.5 cm and 3 cm, in particular between 0.75 cm and 1.25cm. The circular third electrode strips preferably have an axial extentin the range 1 μm to 5 mm, preferably in the range 100 μm to 4000 μm.

The third electrode contacts of the third electrode structure aredisposed axially centrally between both third electrode strips and havean axial extent such that the respective axial distance to the secondelectrode strips is larger than their actual axial extent.

Particularly having regard to the possibility of carrying outdepolarizing measures, instead of a third electrode structure, it ispossible to envisage disposing three axially separated third electrodestructures between the third electrode strips simultaneously withconfiguring the respective first electrode structure within the firstelectrode assembly. For completeness alone, it should be mentioned thatit would also be possible to envisage even more than three first andthird electrode structures between the respective first and thirdelectrode strips. Thus, three, five, seven or more odd numbers of firstand/or third electrode structures could be provided.

In a preferred exemplary embodiment, a third electrode structurecomprises four third electrode contacts the electrode contact area ofwhich is respectively less than one quarter of the contact area of arespective third electrode strip. Since the first or third electrodestrips provided in both the first and also in the third electrodeassembly each act as a ground or counterpole for polarization of therespective first or third electrode structure, because of chargesymmetry considerations, the surface areas of the first and thirdelectrode strips are each selected so as to be identical. However, anindividual independent surface area selection may also be envisaged whenconfiguring the first and third electrode strips.

Furthermore, it has been shown to be advantageous if all electrodes ofthe third electrode assembly, that is the third electrode contacts andthird electrode strips, are produced from an electrically conductivematerial which has a lower charge transfer capacity than the electrodematerial from which the first electrode contacts of the first electrodeassembly are formed. A particularly suitable material with aparticularly high charge transfer capacity has been shown to be iridiumoxide for the production of the respective first electrode contacts ofthe first electrode assembly, whereas the material for the thirdelectrode contacts and third electrode strips consists of platinum or anelectrically conductive polymer.

All of the electrode contacts of both the first and also third electrodeassembly are preferably flush with the support substrate surface of thesupport substrate or set back with respect to thereto, so that they donot protrude beyond the support substrate surface, in order to provideas inocuous a surface contact as possible with the epineurium of thenerve fiber bundle. Because of the non-invasive surface contact, theimplantable electrode assembly can easily be applied along the nervefiber bundle and positioned, whereby the epineurium is not irritated atall or is only irritated to a minimal extent.

In order to combat further implantation-related tissue irritation andinflammatory reactions, at least one of those regions of the supportsubstrate having a biocompatible polymer which comes into direct surfacecontact with the nerve fiber bundle may be provided with an inflammationreaction-inhibiting substance. A furtherway for reducing mechanicalirritation to the nerve fiber bundle which could arise due to surfacecontact with the cuff electrode relates to rounding axial marginal edgesof the support substrate surrounding the nerve fiber bundle in a mannersuch that in the region of the right cylindrical support substratesurface orientated towards the nerve fiber bundle, the biocompatiblesupport substrate respectively has opposing edge regions where thesupport substrate has a greater substrate thickness than in theremaining support substrate region, wherein the edge regions haverounded marginal edges.

In the region of the third electrode assembly which acts to carry outelectrical inhibition of localized nerve fibers, in a further preferredembodiment, at least one and preferably a plurality of optical waveguideopenings or apertures are provided through which light can be applied orcoupled through the epineurium of the nerve fiber bundle. The opticalwaveguide openings are preferably disposed axially adjacent to bothsecond electrode strips and match the form, size and distribution of thethird electrode contacts of the third electrode structure. By providinga plurality of spatially separated optical waveguides which lead to thesupport substrate surface facing the nerve fiber bundle, coherent ordifferent optical signals with different wavelengths can be applied tothe nerve fiber bundle for the purposes of optically activatingoptogenetic neuronal reactions within the nerve fiber bundle. In thismanner, by means of a plurality of suitably disposed optical waveguideopenings or apertures within the nerve fiber bundle, neuronal activationor inhibition reactions can be locationally selectively triggered as analternative to or as a complement to the neuronal processes caused bythe electrode contacts can be undertaken.

As already mentioned, the implantable electrode assembly in accordancewith the invention is applied along the nerve fiber bundle in a mannersuch that the third electrode assembly lies along the nerve fiber bundlein the direction towards the heart. This ensures that efferent nervefibers can be inhibited, whereas the first electrode assembly orientatedtowards the brain along the nerve fiber bundle can be used for thepurposes of selective stimulation of localized afferent nerve fibers,that is nerve fibers which lead to the brain. If it is necessary toinhibit afferent nerve fibers selectively, then the modified implantableelectrode assembly may be implanted along the nerve fiber bundle in theopposite orientation. In a further possible embodiment, a secondinhibiting third electrode assembly is provided which is providedaxially adjacent to the first electrode assembly opposite the thirdelectrode assembly.

Intracorporeal implantation of the electrode assembly surrounding thenerve fiber bundle in a cuff is also confronted with the fundamentalproblem that the electrode strips and electrode contacts applied to thepolyimide support substrate are constantly exposed to a moist medium,whereupon degradation may occur, in particular at the flat connectionsbetween the electrode contacts and the polyimide support substrate,which leads to local detachment and, associated therewith, at least tocontact degradation via which, finally, the efficiency of the electrodeassembly is compromised. In order to combat these detachment occurrencesbetween metallic electrode contacts and the polyimide support substrate,in a preferred embodiment, at least the first and third electrode stripsare each provided with at least one local opening, wherein the surfacesof the first and third electrode strips are connected to the supportsubstrate or the support substrate surface so that the constituentpolymer or polyimide of the support substrate at least partiallypenetrates through the at least one opening. In this manner, improvedmechanical anchoring of the respective electrode strips with the supportsubstrate is obtained.

A further possibility for an enduringly stable connection between theelectrode contacts or electrode strips and the biocompatible polyimideor polymer material of the support substrate is reflected in a specialconfiguration of the electrode contacts or electrode strips and in aspecific integration of the electrodes into the support substrate. Inthis regard, the first and third electrode strips in particular eachhave a metallic base plate with a flat upper and lower side with atleast one, preferably a plurality of structural elements locallyprotruding orthogonally from the upper side of the base plate, which arepreferably configured as columns, ribs, sleeves or webs. The metallicbase plate is completely surrounded by the biocompatible polymer of thesupport substrate with the exception of a first surface region of the atleast one structural element which is orientated facing the supportsubstrate surface and which does not protrude over it. This reduces thefreely accessible electrode contact surface area on the supportsubstrate surface, but because of the hermetic encapsulation of the baseplate and also the one piece structural elements associated therewith,with the exception of the surface regions orientated to face the supportsubstrate surface, it is completely surrounded by the biocompatiblepolymer of the support substrate. Ingress of liquid medium or moistureassociated with the medium between the electrode strips and thebiocompatible polymer of the support substrate is made substantiallymore difficult, so that degradation events can be largely excluded. In afurther preferred embodiment, preferably between the lower side of themetallic base plate and the biocompatible polymer of the supportsubstrate a layer of bonding agent or an assembly of layers of bondingagent is inserted, which combats possible moisture-related detachmentincidents.

The implantable assembly in accordance with the invention advantageouslyenables a method for locationally selective acquisition of neuronalelectrical signals which propagate along at least one nerve fibercontained in a nerve fiber bundle of a human or animal organism, as wellas for selective electrical stimulation of the at least one nerve fiber,to be carried out. Particularly in the case of the electricalstimulation of afferent nerve fibers, that is nerve fibers along whichneuronal electrical signals are guided to the brain, the electricalstimulation in accordance with the invention causes no or no significantirritation of the brain function because it is not possible to make adistinction in the brain between natural neuronal electrical signals andelectrical stimulation signals. The method in accordance with theinvention is characterized by the following steps of the method:

Firstly, neuronal electrical signals propagating along a nerve fiberwhich are to be manipulated are locationally selectively acquired. Thisstep may be carried out with an electrode assembly which is known perse. On the basis of the acquired natural neuronal electrical signals,“artificial” electrical signals are generated having a signal durationand temporal amplitude corresponding to the acquired natural neuronalelectrical signals. Depending on the therapeutic goal, for examplereducing or raising the blood pressure, the “artificially” generatedelectrical signals are modified in a manner such that the amplitude ofthe electrical signal is raised or reduced at least within a temporalpart section of the signal duration. Preferably, the temporal amplitudeprofile of the electrical signal is coherently raised or reduced in itsentirety, that is over the entire signal duration of the electricalsignal. In this manner, electrical stimulation signals are obtainedwhich are applied to the nerve fiber in temporal phase with the neuronalelectrical signals. This means that the natural neuronal electricalsignals are temporally coherent, that is their temporal signal durationand temporal sequence along the nerve fiber can be overwritten by anelectrical stimulation signal. This temporally coherent overwritingprocedure means that the information within the natural neuronalelectrical signal is replaced by artificially produced informationimpressed with the electrical stimulation signal.

Because the electrical stimulation signals propagate along the afferentnerve fibers in the same temporal sequence and with the same temporalsignal duration as the original neuronal signals, it is not possible todifferentiate the neuronal electric signals from the electricalstimulation signals in the brain.

In order to prevent electrical stimulation signals applied to therespective nerve fiber from propagating bidirectionally along the nervefiber, in a preferred development, temporally prior to and/or duringapplication of a respective electrical stimulation signal to the nervefiber, an electrical inhibition signal is applied to the nerve fiber ina manner such that the electrical stimulation signal can only propagateunidirectionally along the nerve fiber. Suppression of signalpropagation in the unwanted nerve fiber direction is preferably carriedout with the aid of an additional electrode assembly which is separatefrom the electrode assembly acting to apply the electrode stimulationsignals, which is positioned in the vicinity of the location at whichthe electrical stimulation signal is applied along the nerve fiber andin the opposite direction to the direction of propagation of theelectrical stimulation signal.

All other advantageous features of the implantable assembly will beillustrated below with reference to the figures.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be described without limitation to the generalinventive concept and with the aid of exemplary embodiments made withreference to the drawings, in which:

FIG. 1 shows a block diagram of all of the components of the implantableassembly in accordance with the invention;

FIGS. 2a and 2b show an implantable electrode assembly in accordancewith the prior art;

FIG. 3 shows time diagrams to illustrate the ECG signal and the neuronaltime signal correlated with the blood pressure;

FIG. 4 shows an illustration explaining the stimulation signal composedof n individual pulses as well as explaining an individual pulse;

FIG. 5 shows an illustration of two alternative operational modes forthe implantable assembly for blood pressure regulation;

FIG. 6 shows a top view of a diagrammatic implantable electrode assemblywith a third electrode assembly for selectively inhibiting nerve fibers;

FIG. 7a shows an illustration of an electrode strip with an opening;

FIG. 7b shows a detailed representation of an electrode strip integratedinto the support substrate; and

FIG. 7c shows an alternative configuration of a structural element;

FIG. 8a-f illustrate an additional reinforcing cuff for the implantableelectrode assembly;

FIG. 9 shows a hydraulic application structure for the implantableelectrode assembly; and

FIG. 10 shows a flow diagram for carrying out the electrical stimulationof a nerve fiber.

DETAILED DESCRIPTION OF THE INVENTION

FIG. 1 shows a block diagram which illustrates the individual componentsof the implantable assembly which respectively are interconnected viaprimarily bidirectional electrical communication pathways as shown withconnecting arrows. The individual communication pathways may be in theform of wired or wireless connecting lines via which the electricalsignals for informal data transfer as well as electrical energy transfercan be transmitted bidirectionally.

The main components of the implantable assembly are the implantableelectrode assembly E, the analysis and control unit A/S, a firstcomparator unit K1 electrically connected to the analysis and controlunit A/S, a first function generator F1 also connected to the analysisand control unit A/S, as well as a first signal-current converter SSW1connected to both the first function generator F1 directly or indirectlyas well as to the implantable electrode assembly E.

In a first embodiment, the implantable electrode assembly E correspondsto an electrode assembly which is known per se, as illustrated in FIGS.2a and 2b , which can be applied around a nerve fiber bundle in a cuff,wherein for the purposes of selective detection of electrical neuronaltime signals, first electrode structures 3 configured as tripoleassemblies are preferably provided, which are respectively axiallybordered on both sides by first electrode strips 5 which are in the formof rings when implanted as shown in FIGS. 2a and 2b , in this regard.

In addition, the implantable electrode assembly E is provided with atleast one electrode for acquisition of the ECG signal. As an example, itis possible for an ECG signal of this type to be picked up with the aidof the reference electrode 12 in the implantable electrode assemblyillustrated in FIG. 2 a.

The electrical information detected with the aid of the electrodeassembly E, both the ECG signal as well as the neuronal electrical timesignal correlated with the blood pressure, are supplied to the analysisand control unit A/S in a time-resolved manner for further analysis.Preferably, a timer unit T is used for the time-resolved acquisition andtransfer of the electrical signals to the analysis and control unit A/S.FIG. 3 provides a better understanding of the function of theimplantable assembly. [It shows the temporal relationships between anECG signal acquired with the aid of the second electrode assemblyapplied around the vagus nerve in the region of the carotid artery. Seewave form A The natural pulse wave or blood pressure wave PW through theaorta is shown as wave form B which, for example, can be acquired with adedicated blood pressure sensor within the aorta in the immediatevicinity of the heart, as well as a neuronal time signal ZS shown aswave form C which is correlated with the blood pressure and derived fromthe neuronal electrical signal.

The baroreceptors in the wall of the aorta are stimulated by themechanical pulse wave PW, whereupon the baroreceptors transmitfrequency-encoded neuronal electrical signals which depend on thestrength of the pulse wave PW. This synchronous stimulation of severalhundred baroreceptors in total produces the neuronal electrical signalwhich can be picked up via the cuff electrode applied around the vagusnerve.

To technologically stimulate the vagus nerve for the purposes ofoverwriting natural neuronal electrical signals which are directed alongthe vagus nerve for the purposes of therapy, at least two time delayeffects have to be taken into account which have to be considered orcompensated for when carrying out the engineered stimulation in order tomake the stimulation appear as natural as possible in order to preventthe brain from subsequently being irritated by the engineered signal.

On the one hand, this concerns the time delay ZV between the start ofthe ECG signal, or the R wave, of the ECG signal, as shown as FIG. 3A.The rise of the blood pressure wave PW in the aorta, is at point P1 inFIG. 3B. On the other hand, this concerns the time delay ZV* betweenstimulation and transduction of the baroreceptors and the neuronalelectrical time signal ZS until it has reached the region at which thecuff electrode E should overwrite the natural blood pressure signal.This time delay ZV* is typically selected to be between the point P1 anda first maximum M of the neuronal electrical time signal ZS.

The neuronal electrical time signals ZS may appear different, butusually they have a “sombrero” shape and thus have several “vibrations”.It might initially appear to be odd that the pulse wave signal PW fromthe baroreceptors is not encoded as a “wave form”. The reason for thisis because of the tripolar configuration of the first electrodeassembly. Thus, the “single peaked” natural neuronal electrode pulsewave signal runs along the vagus nerve in the longitudinal directionpast the three electrode structures of the first electrode assembly andcan polarize them temporally one after the other. In this manner, themonophase neuronal electrical signal is converted into the multiphaseneuronal electrical time signal ZS.

The derived multiphase neuronal electrical time signal ZS also alwayssits temporally between a characteristic flank rise point P1 and a flankfall point P2 of the pulse wave PW. That is within the time window T1which corresponds to the temporal duration of the pulse wave PW.

Considering the time delays ZV and ZV* discussed above, the electricalstimulation signal has to be generated within the time window ZF. SeeFIG. 3D. The electrical signal can be applied via the first electrodeassembly to the vagus nerve for the purposes of a selective stimulationof the at least one baroreceptive nerve fiber.

In contrast to the acquisition and metrological use of the ECG signal,determining the neuronal electrical time signal ZS correlated with theblood pressure as shown in FIG. 3C, requires special signal processingor signal preparation, especially if the signal level of the measuredtime signal ZS correlated with the blood pressure cannot bedistinguished from the surrounding electrical noise level. In thisregard, with the aid of the neuronal electrical signals obtained fromthe implantable electrode assembly, preferably, coherent averaging,preferably with the ECG signal as a trigger, is undertaken, wherein allof the parts of the signal undergo additional amplification whichreproducibly follow the blood pressure. Further details in this regardcan be obtained from the contribution cited above by Dennis T T Plachta,Oscar Cota, Thomas Stieglitz, Mortimer Gierthmuehlen, “SelektiveAbleitung and Stimulation fur ein blutdrucksenkendes Implantat unterVerwendung von Vielkanal-Cuff-Elektroden” [Selective Recording andStimulation for a Blood Pressure-Reducing Implant Using Multi-ChannelCuff Electrodes], tm-Technisches Messen, 2013, vol 80 (5), pp 163-172.

With the aid of the neuronal electrical time signal ZS correlated withthe blood pressure, which is shown in FIG. 3C, with its temporallyvarying amplitude profile, the time delay ZV to the ECG signal can bedetermined as shown in FIG. 3A. At this point, it should be noted thatthe neuronal electrical time signal ZS correlated to the blood pressure,which can be determined with the implantable assembly, only correspondsto a relative blood pressure value, that is the electrical potentialsrise and fall along with the blood pressure. The time signal maximumdoes not constitute an absolute blood pressure in mm Hg. Absolute bloodpressure determination thus requires an additional external or internalreference sensor to be provided, with which the absolute blood pressurecan be acquired. For the purposes of calibration of the time signal ZSobtained with the implantable electrode assembly, preferably, atechnical blood pressure sensor which is also implantable is used, forexample a tip catheter, which is known per se, or an extracorporeallypositionable blood pressure cuff. In this regard, FIG. 1 shows thereference blood pressure sensor SB as a further component which does notnecessarily have to be configured as an implantable unit. Preferably,the absolute blood pressure determined with the aid of the referenceblood pressure sensor SB is also fed to the analysis and control unitA/S in a time-resolved manner. The time is recorded by a clock UH whichexchanges data with the reference blood pressure sensor SB.

In order to stimulate the baroreceptive nerve fibers electrically withinthe nerve fiber bundle surrounded by the implantable electrode assemblyE in a cuff which is required for effective blood pressure therapy, ananalysis of the ECG signal as well as the neuronal electrical timesignal correlated with the blood pressure is required. The analysis inthis regard takes place in the analysis and control unit A/S, with theaim of determining exactly that point in time at which the brain expectsthe baroreceptive signals transmitted via the baroreceptive nervefibers. The technical electrical stimulation of the nerve fiberstransmitting the blood pressure signals should also match with thenatural blood pressure signal delivery regarding timing, temporalduration and the qualitatively temporally changing signal form. The ECGsignal is acquired in a monopolar manner as an artefact of the timer ortrigger signal, for example, via the reference electrodes 12 as shown inFIG. 2A. The ECG signal is transmitted to the analysis and control unitA/S as the time signal. Next, the time delay ZV between the ECG and thenatural pulse wave PW is determined in the analysis and control unitA/S. In this regard, in particular, the time difference between the Rwave of the ECG signal and a characteristic signal flank point P1 alongthe rising starting flank of the blood pressure wave PW is used. Thetime delay ZV in a person with a normal pulse (65 bpm) will be <200 msSee the time axis in seconds in FIG. 3A. Furthermore, in the context ofthe analysis and control unit A/S, the characteristic pulse duration T1of the pulse wave PW is measured, which is given by the temporalseparation between the first signal flank point P1 and a second signalflank point P2 along the falling signal flank.

Furthermore, within the analysis and control unit A/S and takingbiologically conditioned delays into consideration, for example timedelays conditioned by transduction of a mechanical event (pulse wave)into a bioelectrical signal and/or by conversion of an engineeredcurrent signal into a bioelectrical neuronal potential and/or by thetime delays brought about by the characteristic line velocities alongneuronal fibers, a corrected time delay ZV* is determined which is takeninto consideration when generating a stimulation signal.

Thus, the at least one baroreceptive nerve fiber is electricallystimulated within a specific time window ZF which lies in a defined timedelay ZV+ZV* with respect to the acquired ECG signal. This is carriedout with the aid of the function generator F1, which generates astimulation signal SSI composed of a plurality of n individual pulsesand which matches the neuronal electrical signal SN correlated with thenatural blood pressure, as shown in FIG. 4A, in phase and temporalamplitude. In this regard, it should be noted that the natural neuronalelectrical signals SN propagated along baroreceptive nerve fibers areidentical to the form and pulse duration of a blood pressure or pulsewave PW having regard to the temporal duration T_(SN) and amplitudeprofile.

The function generator F1 then modulates the amplitudes of the nindividual pulses EP. in FIG. 4A the stimulation signal SSI is composedof 13 individual pulses but in reality, 100 to 200 individual pulsesproduce a stimulation signal and thus approximates to the biologicalpressure profile in the stimulation signal SSI acquired with theimplantable electrode assembly E as an envelope function. In order toestablish the temporally variable amplitude profile of the stimulationsignal SSI, that is the matched amplitudes of the individual pulses EPwithin a stimulation signal, the pulse duration T1 of the time signal szcorrelated with the blood pressure as well as its maximum amplitudeA_(max) are employed. Advantageously, the pulse duration T1 as well asthe maximum amplitude A_(max) are determined within the first comparatorunit K1.

Each individual pulse EP has characteristic parameters which as shown inFIG. 4B. Thus, each individual pulse EP has a cathodic signal portion KTand an anodic signal portion AT. The anodic signal portion AT of eachindividual pulse EP has an anodic amplitude in amperes, E1, as well asan anordic pulse width E4. Similarly, the cathodic signal portion KT hasa cathodic amplitude in amperes, E2, and a cathodic pulse width E3. Therepetition rate E5 is measured in Hz. The repetition rate E5 does nothave to have a fixed frequency. It has been shown that neuronal systems,neuronal nerve fibers, can best be stimulated if external electricalactivation follows or corresponds to the natural typical pattern ofneuronal activity, that is with a distribution function which preferablyis a Poisson distribution. Production of the stimulation signal SSIcomposed of a plurality of n individual pulses EP is preferably carriedout with the first function generator F1 in a manner such that the twophases of each individual pulse EP, that is the surface areas of theanodic signal portion AT and the cathodic signal portion KT areidentical. Otherwise the electrode contacts, that is at least theelectrode contacts 4 of the tripolar electrode structures 3, as shown inFIG. 2, would become charged, whereupon subsequent electricalstimulations would be applied to the at least one selected nerve fiberwithin the nerve fiber bundle with a significantly smaller efficiency.Furthermore, lack of charge balance can lead to corrosion by means ofredox reactions if a DC voltage is built up by the polarization whichexceeds the water window boundaries. The individual anodic and cathodicsignal portions AT, KT of each individual pulse EP are produced by thefirst function generator F1 in the form of square wave signals.

It has also been shown to be advantageous when the signal flanks of eachindividual pulse EP are advantageously “rounded off” to a certain extentin order to reduce the corrosion effects arising at the metal contactsof the individual electrodes of the implantable electrode assembly,service life can be improved. An engineered signal flank rounding ofthis type, in particular of the repolarization flank E6, shown at thebottom left of the of FIG. 4B along with the improved electrochemicalproperties discussed above proves to be even better with regard to thebiological effectiveness during electrical stimulation of the at leastone selected nerve fiber. In this regard, a first modulator M1 isconnected immediately downstream of the first function generator F1 seenin FIG. 1. The modulator M1 can primarily take the rectangularrepolarizing signal portion AT and temporally extend or smooth itcompared with the polarizing signal portion KT. As a result, both signalportions AT and KT have coherent, that is identical signal strengths inorder to allow complete repolarization of the electrode contacts.Alternatively or in combination with the above measures for rounding atleast the repolarizing signal portion AT, a further advantageousinfluence that the first modulator M1 has on each of the individualpulses EP generated by the first function generator F1 is the temporaldecoupling between the cathodic signal portion KT and the anodic signalportion AT by means of a temporal break E7 as shown in FIG. 4, bottomright hand side. As a result, an extremely long signal flank between thecathodic and anodic signal portions KT and AT is avoided, whereuponunwanted neurostimulating artefacts can be excluded. Clearly it is alsopossible to modulate the temporal duration of the break E7.

All of the individual pulse characteristics E1 to E7 described above andshown in FIG. 4 can be individually set up and adjusted by the firstmodulator M1.

The implantable assembly can autonomousy decide, as a function ofindividual regulation requirements for the purposes of levelling theblood pressure, as to whether, when and to what strength and durationelectrical stimulation signals SSI should be applied to the at least onebaroreceptive nerve fiber. In this regard, the implantable assembly inaccordance with FIG. 1 is provided with at least one second comparatorassembly K2 which is electrically connected to the analysis and controlunit A/S. The second comparator assembly K2, which may be housed in thesame unit as the first comparator unit K1, compares at least onecharacteristic signal level of the neuronal time signal ZS correlatedwith the blood pressure with a reference signal which is preferablystored in a Lookup table LT, which is connected to both the analysis andcontrol unit A/S and the comparator unit K2, which generates acharacteristic difference level on a basis of what the analysis andcontrol unit A/S establishes at least as the temporal amplitude profile,with the temporally variable amplitude of the stimulation signal SSI.Finally, advantageously on the basis of at least the generateddifferential level value, all of the stimulation parameters E1 to E7 canbe varied and coordinated so that all individual pulse forms can beindividually selected in order to compose a stimulation signal SSI to beapplied to the at least one baroreceptive nerve fiber.

Clearly, in addition to the reference signal stored in the Lookup tableLT, further information characterizing the physiological condition ofthe respective patient may be stored for the purposes of electricalstimulation of the at least one baroreceptive fiber, such as, forexample, information which characterizes the mobility status of thepatient, the differential level value, acquired absolute blood pressure,etc.

Thus, in an advantageous embodiment the implantable assembly is providedwith an accelerometer BS which is preferably integrated into theimplantable module, in which the analysis and control unit A/S, thefirst and second comparator unit K1 and K2, the first function generatorF1 as well as the first signal-current converter SSW1 are housed. Theaccelerometer BS is electrically connected to the analysis and controlunit A/S and thus can supply the generated acceleration information tothe analysis and control unit A/S for further analysis. It is alsopossible to use an extracorporal accelerometer positioned on the patientwhich provides acceleration information which can be communicated to theanalysis and control unit A/S wirelessly, for example by inductive datacoupling. The at least one and preferably triaxial accelerometer ormovement sensor BS can record the physical activity of the respectivepatient, so that blood pressure rises conditioned by movement can betaken into consideration and recognized as such by the implantableassembly so that it does not lead to a blood pressure reducingstimulation of the at least one baroreceptive nerve fiber.

In addition to possibly producing and positioning a triaxialaccelerometer or movement sensor outside the body, further extracorporalunits may advantageously be provided such as, for example, an energysource ES, a storage module SM as well as a signal and energy supplyunit SES. In order to transmit all electrical signals, and also totransmit electrical energy, wireless induction-based signal and energytransmission technology is used.

All information which is fed to the analysis and control unit A/S, inparticular the intracorporeally acquired neuronal time signals ZScorrelated to blood pressure as well as all extracorporeally providedinformation can be stored in the Lookup table LT and be updatedappropriately, so that the regulation mechanism at the basis of theimplantable assembly can constantly refer to up-to-date information. Asan example, in this manner, the neuronal time signals ZS correlated withthe blood pressure picked up with the aid of the electrode assembly E,which only represents relative blood pressure signals, can be calibratedwith up-to-date, absolute blood pressure values which can be acquiredwith the aid of the intracorporeal or extracorporal blood pressuremeasurement system SB. Furthermore, the implantable assembly configuredin accordance with the invention enables self-regulating monitoring ofthe stimulation signals applied to the at least one baroreceptive nervefiber wherein, with the aid of the electrode assembly E, organicfeedback of the stimulations which occur can be recorded so that what isknown as a closed loop regulation function can be obtained.Alternatively to or in combination with the Lookup table mentionedabove, a further storage zone may also be provided to hold informationor signals, so that signals themselves can be stored when, for example,a state estimator and Kalman filter is used for regulation and laggingsignals can affect the manipulated variable for the adjustments.

Referring now to FIG. 5, two different blood pressure regulation modeswill now be discussed with which the implantable assembly can be used toaffect the blood pressure. In both diagrams shown in FIG. 5, therespective top graph shows the blood pressure along the time axis t. Therespective bottom graph in both diagrams shows the stimulation amplitudefor a respective stimulation signal SSI in diagrammatic manner. In thecase of the blood pressure regulation illustrated in the top of FIG. 5,it can be seen that immediately after activation and application of astimulation signal SSI which has a stimulation amplitude A3, a dip DE,which significantly reduces the blood pressure is triggered. If thestimulation signal SSI is repeated at a repetition rate t1, then thisresults in a rapid drop in blood pressure until a desired blood pressurevalue is reached.

On the other hand, the blood pressure regulation mode B illustrated inthe lower diagram results in a different response to naturalphysiological blood pressure regulation. In this case, then, thestimulation signals SSI are activated and applied with a much smallerstimulation amplitude A4 than in the case of the stimulation amplitudeA3 in the regulation mode A described above, by use of a smallerstimulation signal amplitude A4 of this type, no acute dip DE isproduced in the blood pressure value. Furthermore, if the temporalseparation between the individual stimulation signals SSI are selectedto be large enough in the case of regulation mode B (see time axis inminutes), that is very much longer than in the case of mode A, thisleads to a very slow but steady drop in blood pressure, as can be seenfrom the blood pressure function in the case of regulation mode B. Bymeans of regulation mode B, also termed a “secondary effect” in contrastto the “primary effect” which describes regulation mode A, a lot ofenergy can be saved when operating the implantable assembly.Furthermore, the load on the nerve tissue and also on the electrodes issubstantially smaller, and in addition the blood pressure can beregulated carefully. Both the stimulation amplitude A4 and also thetemporal repetition rate t2 can be selected individually in order to seta desired reduced blood pressure. The modus operandum described asregulation mode B is preferred for the therapy of chronic hypertension,whereas regulation mode A, described as the primary effect, may be ofapplication in cases of hypertonic crisis.

The implantable assembly in accordance with the invention canautomatically change between the two regulation modes during operationas a function of the occurrence of specific blood pressure situations,that is if blood pressure spikes are to be reduced as quickly aspossible, then regulation mode A is suitable, but if on the other handslow blood pressure corrections are preferred, then regulation mechanismB is used. In order to decide which of the two regulation mechanisms areto be applied, all of the updated recorded information in the Lookuptable as well as the information supplied to the analysis and controlunit may be used.

As already discussed in connection with FIG. 4, the n individual pulsesEP are composed of a cathodic and an anodic signal portions KT and AT,so that both polarization signal surfaces cancel each other out mutually(charge balanced stimulation), a residual polarization of the respectiveelectrodes contributing to stimulation can be avoided. Despite thesemeasures, it is possible that an admittedly small residual polarization(charge) on the electrodes cannot be excluded, with subsequentindividual stimulation pulses affecting both pulse form and pulsestrength. These unwanted effects caused by residual polarization have tobe avoided.

To this end, in a further preferred embodiment of the implantableassembly in accordance with the invention, an electrode impedancemeasurement unit EM is provided. See FIG. 1. The unit EM which formspart of the implantable module or is disposed on the support substrate 1and is electrically connected to the electrode assembly E as well aswith the analysis and control unit A/S. The electrode impedancemeasurement unit EM is configured in a manner such that between each ofthe n individual pulses EP, an impedance measurement is made at least atthe electrodes of the first electrode assembly and thus measures theirpolarization. The electrode impedance measurement unit EM is alsoconnected to a first depolarization unit EE1 which is also a part of theimplantable module or is positioned on the support substrate 1. In theevent that a residual polarization is detected by the electrodeimpedance measurement unit EM, the first depolarization unit EE1 candepolarize individual electrodes by briefly activating the affectedelectrodes selectively by applying electrical signals. Furthermore, thefirst depolarization unit EE1 not only detects any residual polarizationat the electrodes involved in stimulation between each individual pulsebut also removes the residual polarization (charge) appropriately.Moreover the unit EZZ also carries out an appropriate polarizationmeasurement and appropriate active depolarization after each individualstimulation signal SSI. As a result, all of the individual pulses EP canbe produced free from or substantially free from polarization effects,so that each individual stimulation signal SSI is generated underidentical electrical circumstances by the electrode assembly. In thismanner, buildup of a DC voltage underlying the sequence of stimulationsignals can be prevented.

In a preferred embodiment, the implantable assembly, configured inaccordance with the invention, is provided with an electrode assembly Ewhich is modified compared to the implantable electrode assembly Eillustrated in FIGS. 2a and 2b , as illustrated in FIG. 6, which will bediscussed further below, and which can actively suppress unwantedpossible signal propagation along the baroreceptive nerve fiber in thedirection of the heart, as can occur with the previously describedelectrode assembly.

To this end, the implantable electrode assembly is provided, on theright cylindrical support substrate surface facing the nerve fiberbundle when implanted, with a third electrode assembly 7 for inhibitingneuronal electrical signals propagating unidirectionally along the nervefiber bundle. The third electrode assembly 7, which will be described inmore detail below, is exclusively or primarily activated in connectionwith the electrical stimulation of the at least one baroreceptive nervefiber. In this regard, a second function generator F2 is provided whichis also integrated into the implantable module and generates anelectrical signal known as a blocking or inhibition signal temporallybefore and/or during the determined time window t1, as shown in FIG. 4.The second function generator F2 as shown in FIG. 1 is also directly orindirectly connected to a second signal-current converter SSW2 whichsupplies the electrical inhibition signal to the third electrodeassembly 7. In the same manner as the first function generator F1, thesecond function generator F2 is also capable of producing individualpulses which are each composed of a polarizing (charging) and arepolarizing (discharging) rectangular signal portion. In this caseagain, because of their polarity, both signal portions (charge)neutralize each other, so that after each individual pulse, almost noresidual polarization (charge) remains at the respective electrodecontacts 9.

Furthermore, a second moderator M2 is between the second functiongenerator F2 and the second signal-current converter SSW2 is a whichamplifies and smooths a signal flank profile associated with adischarging signal portion AT forming a rectangular pulse temporallywith respect to the polarizing signal portion KT and harmonizes thesignal strengths associated with the two signal portions. The measuresconnected to the second modulator M2 are taken for the same reasons asdiscussed above with respect to the first modulator M1. In addition tothe second function generator F2, the second modulator M2 is alsointegrated into the implantable module. Again in the case of the secondmodulator M2, it is also optionally possible to temporally separate thepolarizing signal portion for each individual pulse by means of a zerosignal which can be produced in the second modulator M2 fromrepolarizing signal portions. In this manner, a long steeply fallingsignal flank between the two signal portions is avoided, which couldlead to irritating inhibition effects or to additional stimulation ofthe nerve fibers under the outlying electrodes (what is known as risingbreak excitation).

Inhibition can be carried out with the third electrode assembly 7 eitherby way of what is known as anodal blocking or by the application ofsinusoidal signals with frequencies in the kilohertz region, what isknown as a HF blocking. In the case of an anodal block, at least one ofthe third electrode contacts is polarized anodically, whereupon avoltage is produced at the location of the efferent nerve fiber forsuppressing stimulation of the corresponding nerve fiber. In this case,an additional modulation by the second modulator M2 is not required.Similarly, an inhibition with a high frequency signal application may beintended, wherein a high frequency electrical inhibition signal isapplied to the at least one selected third electrode contact, whereuponthe electric signal transmission mechanisms along the efferent nervefibers briefly come to a halt.

The third electrode assembly 7 for specific inhibition of stimulationsignals propagating along the at least one selected baroreceptive nervefiber unidirectionally, preferably in the direction of the heart, issimilarly connected to the electrode impedance measurement unit EM, inorder to record any residual polarization (charging) at the electrodecontacts 8 and 9 of to the third electrode assembly. In order toappropriately depolarize any residual polarizations, again a seconddepolarization device EE2 is provided which can remove both residualpolarizations between individual pulses and also between any sequentialinhibition signals by metered electrical activation of individualelectrodes.

For the purposes of electrical protection of the implantable assemblywith respect to EMP protection as well as magnetic coupling by means ofMRT, EMP unit is integrated into the implantable module. This unitmonitors the inputs of the electrodes and enables decoupling in theevent of externally evoked fluctuations in potential. In addition, theEMP unit is provided with a magnetic field sensor which, when a strongDC field is detected, activates a temporary self-protection program.

FIG. 6 shows a diagrammatic top view of a preferred implantable cuffelectrode E on the support substrate 1 which is preferably produced frompolyimide. A third electrode assembly 7 is provided, in addition to thefirst electrode assembly 2 for locationally selective detection ofneuronal electrical signals and for the selective electrical stimulationof individual nerve fibers, for the inhibition of at least one selectednerve fiber. To avoid repetition, reference should be made to thediscussions regarding the individual electrodes of the first electrodeassembly 2 as well as the second electrode assembly 12 in the abovedescription of FIGS. 2a and 2 b.

The third electrode assembly 7 for inhibiting the signal propagation ofefferent nerve fibers leading in this case to the heart H comprises twoaxially separated third electrode strips 8 between which a thirdelectrode structure 13 is centred, and which has four separatelydisposed third electrode contacts 9. All of the electrodes 8 and 13 ofthe third electrode assembly 2 are positioned on the support substrate 1or are connected to or are connectable to the analysis and control unitA/S via electrical conductors L. The electrical conductors L mayoptionally comprise a separable connecting structure V.

Optionally, the third electrode assembly 2 comprises optical waveguideassemblies 10 which each comprise four separate optical waveguideopenings 11 distributed in the circumferential direction U. The opticalwaveguides LI run to the individual optical waveguide openings orapertures 11 within the support substrate 1 and can be combinedproximally with a single light source LQ or with separate light sourcesLQ with different wavelengths of light, in order to selectivelyontogenetically activate stimulations and/or optically activate andselectively inhibit along specific nerve fibers.

Selection of the geometrical form and size of the individual electrodes,in the first and third electrode strips 5 and 8 as well as the first andthird electrode contacts 4 and 9 can in principle be carried outindividually with respect to each other and in particular comply withthe diameter of the nerve fiber bundle around which the implantable cuffelectrode E can be positioned. Thus, the extent in the circumferentialdirection U of the first and third electrode structures and electrodestrips as well as, if appropriate, the optical waveguide assemblies 10preferably correspond to the length of the circumferential edge of thenerve fiber bundle to be wrapped with the cuff electrode E. The axialseparation of the tripolal electrode assembly should preferably bematched to the diameter and the resulting separation of what is known asthe nodes of Ranvier in myelinized nerve fibers of the nerve fibers tobe stimulated. In the embodiment shown in FIG. 6, the electrodes areshown as rectangular electrode contacts. Advantageously, in particularfor the purposes of avoiding field line densification at the electroderectangle edges, the electrode contacts are at least provided withrounded corners.

This is the case when inhibiting or activating large and myelinizedfibers in man. It is only possible at locations along the nerve fiberwhere these fibers are not myelinzied, that is at what is known as thenodes of Ranvier. With increasing diameter of the nerve fibers, theintervals, that is the axial distances between the nodes of Ranvier arelarger, and so correspondingly, the axial distance between two axiallyseparated first electrode strips 5 must be selected so as to beapproximately the same length as the axial separation of the nodes orsomewhat larger in order to reach the nodes of Ranvier of very largefibers with a sufficiently high statistical probability. The same ispreferably also the case for the axial separation of the third electrodestrips 8.

The total axial extent of the whole cuff electrode E should be matchedto the intracorporeal sizes of the respective nerve fiber bundles,Typically, it should not exceed 4 cm.

The reference electrode contacts 12 applied at the rear of the supportsubstrate 1 act to acquire the ECG signal and, if required, theintracorporeally detectable noise level.

In addition, the support substrate 1 is provided with at least one andpreferably two or three openings 14 reinforced with metallic ringstructures which serve to fasten the implanted electrode assembly CFonto the nerve fiber bundle. Fastening is carried out with a surgicalsuture which is threaded at least once through the openings 14 and isstitched into the tissue surrounding the nerve fiber bundle. In contrastto the region 1B of the support substrate which is rolled into a rightcylinder on which the first and second electrode assemblies 2 and 7 arepositioned so that they contact the surface of the epineurium of thenerve fiber bundle when implanted, the support substrate 1 adjacent tothe support substrate region 1B sits as a flat surface to one side ofthe nerve fiber bundle and protrudes into the surrounding tissue. Themetallic ring structures 14 should help in mechanically accommodatingthe fastening forces along the surgical suture and in preventing damageto the support substrate by incisions.

In order to roll the implantable electrode assembly E with a cuff arounda nerve fiber bundle which is not shown in further detail, on the side Hleading to the heart, the third electrode assembly 7 is disposed alongthe nerve fiber bundle. The first electrode assembly 2 for selectivedetection as well as selective stimulation of localized nerve fibers ispositioned along the nerve fiber bundle on the brain side G.

Preferably, the first and third electrode strips 5 and 8 as well as thefirst and third electrode contacts 4 and 9 are evaporated or sputteredonto the support substrate. Galvanic reinforcement is possible. Laserstructuring of thin metal films is also a possible technology. To jointhe first and third electrode strips 5 and 8 in particular to thesupport substrate 1 permanently, the electrode strips are provided withlocal openings 15 shown as FIG. 7a through which the polymeric materialof the support substrate 1 passes or protrudes. The electrode contact 16of each of the first and third electrode strips 5 and 8 are also flushwith the upper side 1′ of the support substrate and directly contact thesurface of the nerve fiber bundle.

In order to improve the permanent connection of the electrode strips, apreferred embodiment proposes integrating the electrode strips into thesupport substrate primarily in the following manner as shown as FIG. 7b.

With respect to FIG. 7b , the electrode strips 5 and 8 each have ametallic base plate 17 which has an upper side 18 and a lower side 19.In one piece with the upper side 18 of the base plate 17 and over theupper side 18, preferably distributed over the whole upper side, areorthogally projecting structural elements 20, preferably in the form ofcolumns, ribs, webs or having sleeve-like protrusions which have asurface region 21 facing the support substrate surface 1′ which can comeinto direct contact with the epineurium of the nerve fiber bundle. Inaddition, advantageously, a layer of bonding agent 22 is provided atleast between the lower side 19 and the polymeric material of thesupport substrate 1 surrounding the base plate 17. The layer of bondingagent 22 can also be applied to the upper side 18. Particularly suitablelayers of bonding agents of silicon carbide (SiC) as well asdiamond-like carbon (DLC). Preferably, the electrode strips 5 and 8 areproduced from iridium oxide, which counts among those materials with oneof the highest charge transfer capacities.

A further improved variation for the construction of the structuralelements 20 which are positioned in a distributed manner on the upperside of the base plate 17 is illustrated in FIG. 7c . FIG. 7c shows alongitudinal section through a structural element 20 which has anlongitudinal extension LA orientated orthogonally to the upper side 18of the metallic base plate 17 along which the structural element 20 isprovided with at least a second surface region 23 which is orientatedparallel to the upper side 18 of the metallic base plate 17 and ontowhich the layer of bonding agent 22 or an assembly of layers of bondingagent 22′ is applied. The second surface region 23 is separated from thefirst surface region 18 and separately completely surrounded by thebiocompatible polymer via the layer of bonding agent 22 or the assemblyof layers of bonding agent 22′. As can be seen in FIG. 7c , the secondsurface region is orientated facing the upper side 18 of the base plate17. Clearly, it is also possible and advantageous for the layer ofbonding agent 22 or the assembly of layers of bonding agent 22′ toprovided both at a third surface region 24 which is opposite to thesecond surface region 23 and/or at the upper and/or lower sides 18 and19 of the base plate 17.

The number and arrangement of the individual structural elements 20 maybe selected in any manner. However, geometrically arrangedconfigurations KO are preferably used such as, for example, square,pentagonal, hexagonal or higher patterns, as can be seen in FIG. 7 b.

FIGS. 8a-8f illustrate a cuff M which partly surrounds the supportsubstrate 1 of the implantable cuff electrode CE, which comprises theregion of the support substrate 1 on both its lower and upper sideswhich are directly attached to the support substrate region 1B andwhich, in contrast to the support substrate 1B, are not deformedthemselves, by inherent mechanical pretensioning, into a right cylinder,and thus are positioned flush with the epineurium of the nerve fiberbundle when implanted in position.

The cuff M acts first of all to improve handling of the implantable cuffelectrode CE which, because of its very small support substratethickness and also the very fine wired electrode assemblies positionedon the support substrate surface, demands very careful handling by theoperator. The cuff M is preferably designed to be in one piece and isprovided with a lower cuff portion Mu as well as an upper cuff portionMo which are both connected together via a film hinge 25. See FIGS. 8band 8c in this regard. The lower cuff portion Mu is provided with adepression 26 for embedding the support substrate 1, into which thesupport substrate 1 can be inserted. When inserted, the lower cuffportion Mu surrounds the support substrate 1 in the manner shown in FIG.8b , that is the lower cuff portion Mu protrudes out laterally frombeneath the support substrate 1.

The upper cuff portion Mo, which is connected as one piece with thelower cuff portion Mu via the hinge joint 25, matches the shape and sizeof the lower cuff portion Mu. Like the lower cuff portion Mu, upper cuffportion Mo is provided with a depression 27 so that when closed, thecuff M hermetically surrounds the support substrate in the manner shownin FIG. 8a , wherein only the support substrate region 1B protrudes outof the cuff M.

In addition to the improved handling, the cuff M in particular also actsto improve fixing of the cuff electrode CE relative to the nerve fiberbundle. In this regard, the upper cuff portion Mo and lower cuff portionMu are each provided with fastening openings 14′; See FIGS. 8a, 8b and8d which are aligned with the fastening openings 14 positioned withinthe support substrate 1 when the cuff M is folded up. In this manner, itis possible to pass a surgical suture 28 through the openings 14 and 14′of the cuff electrode CE surrounded by the cuff M. In this manner, thefastening opening 14, surrounded by the metallic ring of the cuffelectrode CE, can be relieved by the fastening opening 14′ introducedinto the cuff M. Preferably, the cuff M is produced from a stableplastic material and for example from parylene. To increase the strengthfurther, Mo and Mu may be a polymer hybrid, for example parylene (inner)and silicone rubber (outer). This hybrid has the advantage that thestability of the parylene is combined with the tear strength of thesilicone. In a preferred embodiment, the fastening openings 14′ withinthe cuff M are reinforced by an appropriate thickening of the material.

Window openings 29 are introduced into the upper cuff portion Mo whichensures free access to the reference electrode contacts 12. FIG. 8eshows a cross-section in this regard through the support substrate 1surrounded by the cuff M, on the upper side of which reference electrodecontacts 12 are located, which remain freely accessible because of thewindow openings 29 within the upper cuff portion Mo. Preferably, thewindow openings 29 surround the reference electrode contacts 12 with asteeply inclined border flank 29′, so that this ensures that the entiresurface of the reference electrode contacts 29 can come intoface-to-face physical contact with the surrounding tissue.

In order to ensure that the cuff M remains closed, locking structures Vare disposed between the upper cuff portion Mo and lower cuff portion Muwhich, for example, are a pin 30 and an opposing recess 31 as shown inFIGS. 8c and 8f . When the upper cuff portion and lower cuff portion arebrought together, the pins 30 are urged into contact with thecorresponding recess 31 in which the respective pin 31 is permanentlyretained by friction. FIG. 8f illustrates a locked structure V. Here,the pin 30 on the upper cuff portion Mo protrudes through acorresponding opening in the support substrate 1 and its end sits withinthe recess 31 of the lower cuff portion Mu. Clearly, alternativeembodiments may be utilized for the locking structures as for example inthe form of suitably formed latching mechanisms.

FIG. 9 illustrates a further embodiment which allows the cuff electrodeCE in accordance with the invention to be implanted more easily. Withinthe support substrate 1 is a fluid channel system 32 which is completelysurrounded by the support substrate 1. The fluid channel system 32essentially extends in the region of the support substrate region 1Bwhich, because of inherent pretensioning of the material, takes on theshape of a right cylinder by rolling itself up. If, on the other hand,the fluid channel system 32 is filled with a fluid, preferably water,then the water pressure applied along the fluid channel system flattensout the support substrate region 1 b against the inherent rollup forceof the material. In this regard, the fluid channel system 32 is providedwith fluid channel branches 33 running in the circumferential directionof the sleeve surface of the self-shaping right cylinder. When filled,they force the support substrate region 1B to extend as required.

At least two channel openings 34 within the support substrate 1 areprovided in order to fill the fluid channel system 32. Their sizes andconfigurations are determined such that they open in a fluid-tightmanner at entry and exit openings within the fluid supply or removallines 35 and 36 running inside the cuff M. The supply or removal lines35 and 36 running inside the cuff M are connected fluidically with afluid control system 37 which can be actuated by an operator.

In the event of implantation, the fluid channel system 32 is filled witha fluid, whereupon the support substrate region 1B is extended. When inthis state, the operator places the cuff electrode CE precisely at apredetermined site along the nerve fiber bundle. Next, the fluid channelsystem 32 is emptied by the operator, whereupon the support substrateregion 1B winds itself around the nerve fiber bundle. In the final step,a surgical suture is passed through the fastening openings 14′ of thecuff in order to fix the cuff electrode CE to the surrounding tissue.

In an advantageous embodiment of the above fluid channel system 32, itmay be filled with a shape memory metal or polymer. For the purposes ofactivation, the channel openings 34 are provided with metallic contactsvia which an electrical voltage can be applied along the supply lines 35and 36 to unfold the implantable electrode assembly CE via anappropriately modified control device 37, until the electrodes areeventually in position.

FIG. 10 illustrates a flow diagram which shows the sequence ofindividual steps for blood pressure manipulation or regulation byselective electrical stimulation of nerve fibers. It should be assumedthat for the purposes of the stimulation, the electrode assembly shownin FIG. 6 has been applied locally around the vagus nerve so that theinhibition function is possible. If inhibition could be eliminated, thenthe electrode assembly of FIG. 2a is also suitable. The discussion belowalso refers to the components of the implantable assembly E shown inFIG. 1. In order to avoid repetition, it should be noted that thedecision points marked with “y” denote “yes” and those with “n” denote“no”.

-   -   I) Start: activation of implantable assembly E either manually        or automatically; the analysis and control unit in the form of a        microcontroller is initiated (A/S, FIG. 1).    -   II) Acquisition of ECG signal using the electrodes 12 of the        cuff electrode E as seen in FIG. 6. The analysis and control        unit A/S validates the R wave and separates any EMP errors out        of the signal, wherein a plurality of runs are monitored. The        analysis and control unit A/S then determines the reliability        with which the rzs can be detected. Finally, the analysis and        control unit A/S determines the heart rate.    -   III) Acquisition of blood pressure signal SN using the first        electrode contacts 4, the first electrode strips 5 as well as        the ECG electrode contacts 12 of the cuff electrode E. This is        carried out by coherent averaging of the signals from the middle        row of the first electrode contacts 4 triggered by the rising        flank of the ECG signal which has already been determined.    -   IV) Decision as to whether a change in blood pressure is        present.    -   IVa) Here, the analysis and control unit A/S queries an        up-to-date reference blood pressure (SB) and compares or        calibrates the amplitude of the reference signal with the blood        pressure signal SN.    -   IVb) Validation of the blood pressure and the stimulation        position, if a change in blood pressure is present. See y. The        analysis and control unit/A/S asks the Lookup table LT for blood        pressure signal values SN already stored for this patient as        well as time intervals ZV and ZV* and compares them with the        blood pressure signal SN acquired by averaging. The analysis and        control unit A/S determines the “best” SN of an electrode, this        is tagged as the forthcoming stimulation electrode in the        working memory.    -   V) Determination of the temporal delay ZV between the ECG signal        and blood pressure reference signal. Here, the comparator unit        K1 determines the temporal delay between the R wave and rising        threshold and reference blood pressure.        -   The comparator unit K2 determines the temporal delay ZV*            between the rising threshold of the reference signal and the            neuronal blood pressure signal acquired by the electrode.            See ZS in FIG. 3 and SN in FIG. 4. The start P1 and end P2            of the pulse wave PW are determined from the reference blood            pressure. This interval produces T1. See FIGS. 3B and 3C.            The interval T1 is delayed by the temporal offset ZV+ZV* and            provides the interval ZF as shown in FIG. 3.    -   VI) Decision as to stimulation and selection of stimulation        parameters. The analysis and control unit A/S determines the        time UH and the actual position and movement of the patient        using the accelerometer BS. The analysis and control unit A/S        also determines the impedances of the stimulation electrode via        the inter-stimulus impedance detector. Based on the blood        pressure values, the heart rate, the activity of the patient and        lack of any other contrary control commands that are obtained,        as for example triggered by an external signal by means of the        radio comms module (SES), an error function signal for a        component of the implant (for example an IC of the stimulation        side), or the detection of a strong statistical magnetic field        (EMP), etc, the analysis and control unit A/S decides whether        stimulation should be carried out—yes (y) or no (n).    -   VIa) Stimulation reference values. The analysis and control unit        A/S compares the parameters obtained with those already stored        in the Lookup table LT and the storage module SM and selects        appropriate stimulation parameters (“appropriate” means how        “strong” and how “long” stimulation must be carried out in order        to reduce the blood pressure by x %).        -   The stimulation coordinates such as ZF, the number and form            of the pulses are communicated to the “activating” function            generator F1 (binary). If selective inhibition has to be            carried out at the same time, the appropriate stimulation            parameters for selective inhibition are communicated to the            function generator F2 (binary).    -   VIIa) The analysis and control unit A/S decides upon the        inhibition method (HF or anodal block).    -   VIIb) The analysis and control unit A/S decides upon the        stimulation mode A or B (See FIG. 5).    -   VIIIb) Preparation/modulation of activating stimulation        parameters in accordance with mode A:        -   If mode A is selected for a rapid intervention, a fixed            stimulation sweep with a defined number of individual pulses            is prepared (the duration is not correlated with the ZF            interval, but taken from a table), which is repeated with            predetermined breaks. See FIG. 5, mode A.        -   The analysis and control unit A/S transmits a template to            the first function generator F1, which generates the voltage            signal which is transmitted to the modulator M1.    -   VIIIc) Preparation/modulation of activating stimulation        parameters in accordance with mode B:        -   If mode B is selected, the individual pulses have to be            optimized further. The first function generator F1 produces            an analogous template of a stimulation interval (SSI) and            fits a specific number of individual biphase pulses into the            interval ZF. In this regard, the stimulation signal is            matched to the biological signal. The reference blood            pressure profile is laid over the amplitude of the            individual pulse as an envelope function. See FIG. 4A. The            first function generator F1 transmits the table with the            prepared stimulation sweep to the modulator M1.    -   IX) Matching the phases of the individual pulses of the sweep:        -   The modulator M1 is responsible for both modes and varies            the two phases of each individual pulse See FIG. 4B in order            to produce an ideal individual pulse form for the individual            patient. The modulator M1 transmits the “prepared” voltage            signal in the form of a sweep to the signal-current            converter (SSW1).    -   Xb) Carrying out the activating stimulation:        -   The signal-current converter SSW1 waits for the ECG trigger            signal and waits until the “active window for stimulation            ZF” is reached and transmits the stimulation sweep to the            previously selected stimulation electrode. Between each            individual pulse, the impedance of the stimulation contact            is recorded by the electrode impedance measurement unit EM.            If a polarization is detected by the analysis and control            unit A/S, it gives the active polarization comparator EE1            the order to supply a small extra charge between each pulse            through the stimulation contact as compensation. If this            inter-stimulation compensation is insufficient, then in            addition, after ending the sweep, the intersweep compensator            is activated and compensates for any polarization.    -   VIIIa) Preparation/modulation of the inhibiting stimulation        parameters:        -   The analysis and control unit transmits a stimulation            interval for the inhibition to the function generator F2. As            a rule, this is longer than the activating stimulation, that            is it begins shortly before and ends after the activating            stimulation.        -   The analysis and control unit A/S establishes whether the            second function generator F2 should apply an anodal block,            that is only a monophase block, or whether HF blocking            should be carried out. The function generator 2 also            produces a stimulation (voltage) template. In the event of            an HF block, F2 transmits the voltage signal to the            modulator M2 in order to “smooth” the individual phases.    -   Xa) Carrying out the inhibiting stimulation:        -   The signal-current converter SSW2 converts the signal,            either as an anodal block of the F2 or as a HF block of M2,            into a current signal and feeds it via the inhibition            electrode 9 of the array 13 as seen in FIG. 6. The electrode            impedance measurement unit EM monitors the polarization of            the inhibiting electrodes 9 and if necessary activates the            depolarization unit EE2 via the analysis and control unit            A/S to provide compensation.        -   In the case of an HF block, both can occur, interstimulus            and intersweep; in the case of anodal block, only the            intersweep compensator is active.    -   XI) Analysis of stimulation:        -   The analysis and control unit A/S determines the change in            the blood pressure curve and introduces a repetition. In the            case of mode B, as a primary stimulation parameter, the            number of heartbeats the stimulation covers can be varied.            By means of this function, (patient-specific) feedback of            the mode of operation of the implant is carried out.        -   The outcome of the stimulation is written into the memory so            that it can be used for subsequent comparisons.

LIST OF REFERENCE NUMERALS

1 support substrate 1′ support substrate surface 1B support substrateregion 2 first electrode assembly 3 first electrode structures 4 firstelectrode contacts 4a axial extent of first electrode contacts 4U extentof first electrode contacts in circumferential direction 5 firstelectrode strips 6, 6′ signal detector and generator 7 third electrodeassembly 8 third electrode strip 9 third electrode contacts 9a axialextent of third electrode contacts 9U extent of third electrode contactsin circumferential direction 10 optical waveguide assembly 11 opticalwaveguide openings 12 second electrode assembly, ECG electrode contacts13 third electrode structure 14 fastening openings 15 opening 16electrode strip surface 17 base plate 18 upper side 19 lower side 20structural element 21 surface region 22 layer of bonding agent 22′assembly of layers of bonding agent 23 second surface region 24 thirdsurface region A axial direction A/S analysis and control unit A3, A4amplitudes A_(max) maximum amplitude AT rising signal portion BSaccelerometer de dip E implantable electrode assembly, cuff electrode E1anodic amplitude E2 cathodic amplitude E3 cathodic pulse width E4 anodicamplitude E5 repetition rate E6 repolarization flank E7 break, zerolevel between anodic and cathodic amplitude EE1, EE2 depolarization unitECG ECG time signal EM electrode impedance measurement unit EMP unit forprotection against electromagnetic pulses, EMP and MRT EP individualpulse ES energy storage and energy source F1, F2 function generator gbrain H heart KO geometric configuration KT cathodic signal portion Lconductor LA longitudinal axis of structural element LI optic fiber LQlight source(s) LT Lockup table M maximum M1, M2 modulator NF nervefiber NFB nerve fiber bundle P1, P2 characteristic phase points alongtime signal PW pulse wave, blood pressure wave R R wave of ECG signal SBblood pressure sensor SES signal and energy supply unit SM storagemodule SN natural neuronal electrical signal SSI stimulation signalSSW1, SSW2 signal-current converter T timer unit T1 duration of pulsewave T_(SN) pulse duration of a natural neuronal electrical signal Ucircumferential direction UH clock V connecting structure ZF time windowZS time signal ZV, ZV* time delay

1-43. (canceled)
 44. An implantable assembly for locationally selectiveacquisition of neuronal electrical signals which propagate along atleast one nerve fiber contained in a nerve fiber bundle and forselective electrical stimulation of the at least one nerve fiber,comprising: an implantable electrode assembly disposed on abiocompatible support substrate which is positionable around the nervefiber bundle in a cuff, including a cylindrical support substratesurface orientated to face the nerve fiber bundle in an implanted state,on which a first electrode assembly is positioned for the locationallyselective acquisition of the neuronal electrical signals and theselective electrical stimulation of the at least one nerve fiber, and onwhich a second electrode assembly is disposed to record an ECG signal;an analysis and control unit which is electrically connectible to or isconnected to the implantable electrode assembly, in which the locationalselective acquisition of neuronal electrical signals and the ECG signalare analyzed in a time-resolved manner so that a neuronal time signalcorrelated with a physiological parameter is derivable; a firstcomparator unit, connected to the analysis and control unit, fordetermining a characteristic relative time delay between the ECG signaland the neuronal time signal correlated with the physiologicalparameter; a first function generator connected to the analysis andcontrol unit, which generates a stimulation signal within a time windowdetermined by the analysis and control unit on the basis of the relativetime delay; the stimulation signal comprises n pulses which are in phaseand temporal amplitude with a derived neuronal time signal correlatedwith the physiological parameter; and a first signal to currentconverter coupled to the first function generator and the firstelectrode assembly, which leads the stimulation signal for selectiveelectrical stimulation of the at least one nerve fibre to the firstelectrode assembly (2); and the analysis and control unit, the firstcomparator unit, the first function generator and the first signal tocurrent converter are part of an implantable module.
 45. The implantableassembly as claimed in claim 44, wherein: a second comparator unitconnected to the analysis and control unit, which compares at least onesignal level which is associated with the neuronal time signalcorrelated with the physiological parameter with a reference signal andgenerates a differential level value; and the analysis and control unitestablishes at least a temporal amplitude profile of the stimulationsignal based the differential level value.
 46. The implantable assemblyas claimed in claim 44, wherein: the implantable electrode assemblyincludes a third electrode assembly disposed on the cylindrical supportsubstrate surface which when implanted is orientated to face the nervefiber bundle for inhibiting neuronal electrical signals propagatingunidirectionally along the nerve fiber bundle.
 47. The implantableassembly as claimed in claim 45, wherein: the implantable electrodeassembly includes a third electrode assembly disposed on the cylindricalsupport substrate surface which when implanted is orientated to face thenerve fiber bundle for inhibiting neuronal electrical signalspropagating unidirectionally along the nerve fiber bundle.
 48. Theimplantable assembly as claimed in claim 44, wherein: the implantablemodule includes an electrical energy storage or at least one of aninduction-based signal and an energy supply unit which is electricallyconnected to at least the analysis and control unit.
 49. The implantableassembly as claimed in claim 44, comprising: at least one accelerometeris integrated into the implantable module and an implantableaccelerometer is separated from the module; and the accelerometergenerates acceleration information and is electrically connected to theanalysis and control unit.
 50. The implantable assembly as claimed inclaim 44, wherein: the first function generator produces individualpulses each respectively having polarizing and a repolarizing squarepulse signal components; and a first modulator is connected between thefirst function generator and the first signal-current converter whichamplifies and filters a signal flank associated with the repolarizingsquare pulse signal component temporally relative to the polarizingsquare pulse component and processes signal strength associated with thepulses.
 51. The implantable assembly as claimed in claim 46 or 47,comprising: a second function generator connected to the analysis andcontrol unit which generates an electrical blocking signal which is atleast one of before and during the time window; and wherein the secondfunction generator is coupled to a second signal to current converterwhich supplies the electrical blocking signal to the third electrodeassembly.
 52. The implantable assembly as claimed in claim 50, wherein:the second function generator produces pulses which are each composed ofa polarizing and a repolarizing square pulse portion; and a secondmodulator is connected between the second function generator and thesecond signal to current converter, which amplifies and filters a signalflank associated with the repolarizing square pulse portion temporallywith respect to the polarizing pulse portion and processes signalstrength associated with the pulses.
 53. The implantable assembly asclaimed in claim 52, wherein: the second function generator and thesecond module are integrated into the implantable module.
 54. Theimplantable assembly as claimed in claim 50, wherein: the first or thesecond modulator for each individual pulse separates from eachpolarizing pulse portion from each repolarizing pulse portion by a zerosignal produced by use of the first modulator.
 55. The implantableassembly as claimed in claim 44, comprising: an electrode impedancemeasuring unit which is at least a part of the implantable module,disposed on the support substrate or is connected to the electrodeassembly and to the analysis and control unit; and wherein the electrodeimpedance measuring unit measures impedance of individual pulses atleast at electrodes of the first electrode assembly.
 56. The implantableassembly as claimed in claim 55, comprising: an electricaldepolarization device which is part of the implantable module or isdisposed on the support substrate and is connected to the electrodeassembly and the analysis and control unit; and wherein a residualpolarization is established by the electrode impedance measuring unitand the depolarization device selectively uses applied electricalsignals to depolarize electrodes of the electrical independencemeasuring unit.
 57. The implantable assembly as claimed in claim 48,comprising: a blood pressure measurement system connected to theimplantable assembly, which records blood pressure values which aresuppliable to the analysis and control unit by the induction-basedsignal and energy supply unit; and based on absolute blood pressurevalues, the ECG signal, the neuronal time signal correlated with thephysiological parameter and at least one reference signal, the analysisand control unit causes the first function generator to generate thestimulation signal.
 58. The implantable assembly as claimed in claim 45,comprising: a storage unit, which is coupled with the analysis andcontrol unit for storing a differential level value, accelerationinformation and absolute blood pressure.
 59. The implantable assembly asclaimed in claim 44, comprising: a cylindrical support substrate surfacefacing the nerve fiber bundle including an extension in an axial, in acircumferential direction and on which the first electrode assembly ispositioned; and wherein the cylindrical support surface in the axialdirection, comprises at least three first electrode structures eachhaving at least two first electrode contacts disposed incircumferentially; and at least two axially separated first electrodestrips extending in the circumferential direction and each stripassuming being annularly shaped which encloses the at least threeelectrode structures axially and which are connectable to or areconnected to the analysis and control unit.
 60. The implantable assemblyas claimed in claims 59 and 46, wherein the third electrode assembly isdisposed axially on the cylindrical support substrate surface and facesthe nerve fiber bundle axially adjacent to the first electrode assembly;and comprises at least two axially separated third annularly electrodestrips which extend circumferentially and extend axially between the atleast two third electrode strips, and respectively at least two thirdelectrode structures having electrode contacts uniformly distributedcircumferentially.
 61. The implantable assembly as claimed in claim 60,wherein: the first and third electrode contacts are evenly distributedcircumferentially.
 62. The implantable assembly as claimed in claim 60,wherein the first and third electrode contacts respectively have anaxial extension and an extension orientated circumferentially; theextensions of the first electrode contacts are identical; the extensionsof the third electrode contacts are identical; and the extensionsorientated circumferentially of the third electrode contacts and largerthan the extension of the first electrode contacts orientatedcircumferentially.
 63. The implantable assembly as claimed in claim 62,wherein: the axial extensions of the first and third electrode contactsare identical.
 64. The implantable assembly as claimed in claim 60,wherein: the support substrate surface on which the first and thirdelectrode assembly are positioned is one piece.
 65. The implantableassembly as claimed in claim 60, wherein: an axial distance between thefirst electrode strips is equal to or greater than an axial separationof the third electrode strips, and the axial distance between the thirdelectrode strips measures between 0.5 cm and 3 cm.
 66. The implantableassembly as claimed in claim 60, wherein: the first and third electrodestrips are identical in shape and size; and surface areas of first andthird electrode contact are smaller and in surface area than the surfaceareas of the first or third electrode strips.
 67. The implantableassembly as claimed in claim 60, wherein: the first electrode contactsare metallic material and have a higher charge transfer capacity than amaterial constituting the third electrode contacts.
 68. The implantableassembly as claimed in claim 67, wherein: the metallic material of thefirst electrode contacts is iridium oxide; and the third electrodecontact is a metallic material or is an electrically conductive polymer.69. The implantable assembly as claimed in claim 60, wherein: the firstand third electrode assemblies are operable as a tripolar electrodeassembly wherein first and third electrode strips are polarizableopposite to structure of the first and third electrodes.
 70. Theimplantable assembly as claimed in claim 60, wherein: the thirdelectrode assembly includes at least one optical waveguide assemblycomprising at least two separated optical waveguide openings distributedcircumferentially.
 71. The implantable assembly as claimed in claim 70,wherein: the at least two separated optical waveguide openings areevenly distributed circumferentially; and the optical waveguide openingsrespectively include an axially and a circumferentially orientatedextension corresponding to the second electrode contacts.
 72. Theimplantable assembly as claimed in claim 60, wherein: the firstelectrode contacts and first electrode strips of the first electrodeassembly and the third electrode contacts and the third electrode stripsof the third electrode assembly are positioned on the support substratesurface and do not protrude beyond the support substrate surface. 73.The implantable assembly as claimed in claim 44, wherein: the supportsubstrate is produced from at least one biocompatible polymer includingan inflammation reaction-inhibiting substance in at least in regions ofthe cylindrical support substrate surface facing the nerve fiber bundle.74. The implantable assembly as claimed in claim 44, wherein: thesupport substrate contains a biocompatible polymer.
 75. The implantableassembly as claimed in claim 74, wherein: at least one of the first andthird electrode strips are provided with at least one opening; and atleast one of the first and third electrode strips are connected face toface to the support substrate surface so that the polymer penetrates atleast partially through the at least one opening.
 76. The implantableassembly as claimed in claim 44, wherein: at least two referenceelectrode contacts are positioned on the support substrate to the rearof the support substrate surface.
 77. The implantable assembly asclaimed in claim 44, wherein: a region of the cylindrical supportsubstrate surface is orientated to face the nerve fiber bundle, thebiocompatible support substrate has axial opposing edge regions at whichthe support substrate has a larger substrate thickness than in aremainder of the support substrate region; and the opposing edge regionshave rounded peripheral edges.
 78. The implantable assembly as claimedin claim 44, comprising: a support substrate region, which is notpositioned around the nerve fiber bundle in a cuff, includes at leastone opening that penetrates completely through the support substrate.79. The implantable assembly as claimed in claim 78, wherein: at leastparts of the at least one opening are covered with a metallic material.80. The implantable assembly as claimed in claim 74, wherein: at leastone of the first and third electrode strips includes a metallicelectrode strip substrate having a planar upper side and a lower planarside with at least one structural element protruding orthogonally to theupper side; the planar upper side of the metallic electrode stripsubstrate is orientated parallel to the support substrate surface; andthe electrode strip substrate is surrounded by the biocompatible polymerexcept for a surface region of the at least one structural element whichfaces the support substrate surface but does not protrude beyond thesupport substrate surface.
 81. The implantable assembly as claimed inclaim 80, comprising: one of a layer of bonding agent or an assembly oflayers of bonding agent is at least between a lower side of theelectrode strip substrate and the biocompatible polymer of the supportsubstrate.
 82. The implantable assembly as claimed in claim 80, wherein:one surface region of the at least one structural element or a planeassociated with the surface region is orientated parallel to the supportsubstrate surface; the surface region is accessible from sides of thesupport substrate surface; and at least one single piece structuralelement which is connected with the electrode strip substrate.
 83. Theimplantable assembly as claimed in claim 80, comprising: evenlygeometrically distributed identical configured geometrical structuralelements disposed on an upper side of the metallic electrode stripsubstrate.
 84. The implantable assembly as claimed in claim 80, wherein:the at least one structural element is one of a column, rib, sleeve orweb.
 85. A method for locationally selective acquisition of neuronalelectrical signals which propagate along at least one nerve fibercontained in a nerve fiber bundle of a living human or an animalorganism and for selective electrical stimulation of the at least onenerve fiber, comprising: acquiring neuronal electrical signalspropagating along a nerve fiber at a selected location; generatingelectrical signals with a signal duration and temporal amplitude profilecorresponding to the acquired neuronal electrical signals; modifying theelectrical signals by raising or reducing amplitude thereof at leastwithin a temporal region of the electrical signals to obtain electricalstimulation signals; and applying the electrical stimulation signals tothe nerve fiber in a temporal phase with the neuronal electricalsignals.
 86. The method as claimed in claim 85, comprising: applying ofthe electrical stimulation signals along the nerve fiber so that theneuronal electrical signals are temporally coherently overwritten sothat in a brain of the human or animal a distinction between neuronalelectrical signals and electrical stimulation signals is not possible.87. The method as claimed in claim 85, wherein: at least one oftemporally before and during respective application of an electricalstimulation signal to the nerve fiber, an electrical inhibition signalis applied to the nerve fiber so that the electrical stimulation signalonly propagates unidirectionally along the nerve fiber.